<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65121">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02258152</url>
  </required_header>
  <id_info>
    <org_study_id>SYN120-CL03</org_study_id>
    <nct_id>NCT02258152</nct_id>
  </id_info>
  <brief_title>SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)</brief_title>
  <acronym>SYNAPSE</acronym>
  <official_title>SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotie Therapies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parkinson's Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotie Therapies Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study placebo-controlled, randomized, double-blind study is to assess
      the safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD)
      already treated with a stable dose of a cholinesterase inhibitor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes a Screening Period of up to 6 weeks, a 16 week Treatment Period, and a 2
      week Safety Follow Up Period.

      Final eligibility will be determined at the Baseline Visit. Eligible patients will be
      randomized to receive placebo or SYN120 100 mg once a day (QD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cognitive Drug Research Computerized Cognition Battery (CDR) Continuity of Attention from baseline</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson's Disease Dementia (PDD)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SYN120</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYN120</intervention_name>
    <description>SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).</description>
    <arm_group_label>SYN120</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's Disease Dementia

          -  Patient has a routine caregiver

          -  Taking a stable cholinesterase inhibitor.

          -  Patient has a Montreal Cognitive Assessment (MoCA) 10-23 inclusive

        Exclusion Criteria:

          -  History of any significant neurologic or psychiatric disease other than PD

          -  Any other condition or clinically significant abnormal findings that would make the
             patient unsuitable for the study

          -  Unpredictable motor fluctuations that would interfere with administering assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chris Kenney, MD</last_name>
    <phone>1-650-244-4873</phone>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Richardson, RN</last_name>
      <phone>205-934-0074</phone>
      <email>jhrichardson@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Natividad Stover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Chong, RN</last_name>
      <phone>623-832-6512</phone>
      <email>Christina.Chong@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>David Sprecher, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatta Nahab, M.D.</last_name>
      <phone>858-822-1399</phone>
      <email>fnahab@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Fatta Nahab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease &amp; Movement Disorder Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fannie Levinson</last_name>
      <phone>561-392-1818</phone>
      <phone_ext>6</phone_ext>
      <email>flevinson@parkinsonscenter.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Isaacson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>29847</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Buff Farrow</last_name>
      <phone>706-721-2798</phone>
      <email>bfarrow@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>John Morgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Williams</last_name>
      <phone>312-503-0755</phone>
      <email>pdclinicaltrials@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Tanya Simuni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Blasucci, RN</last_name>
      <phone>312-563-2900</phone>
      <phone_ext>4</phone_ext>
      <email>movement_disorder@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Goldman, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa, Carver College of Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeri Sieren</last_name>
      <phone>319-356-8744</phone>
      <email>jeri-sieren@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Ergun Uc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease &amp; Movement Disorder Center, University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Langhammer, BA,CCRP</last_name>
      <phone>913-588-6989</phone>
      <email>alanghammer@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Rajesh Pahwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University of Maryland Parkinson's Disease &amp; Movement Disorder Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Cines, RN,MD,CRCC</last_name>
      <phone>410-328-0157</phone>
      <email>mcines@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Shulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Bwala</last_name>
      <phone>617-643-0654</phone>
      <email>gbwala@partners.org</email>
    </contact>
    <investigator>
      <last_name>Albert Hung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struthers Parkinson's Center</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Ede, RN</last_name>
      <phone>952-993-2245</phone>
      <email>patricia.ede@parknicollet.com</email>
    </contact>
    <investigator>
      <last_name>Sotirios Parashos, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Neuroscience Institute</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Babek, RN</last_name>
      <phone>908-598-7991</phone>
      <email>diane.babek@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Marcie Rabin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Perry-Trice</last_name>
      <phone>919-684-0865</phone>
      <email>peggy.perrytrice@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Burton Scott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health Sciences</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Dimos</last_name>
      <phone>336-716-8694</phone>
      <email>jdimos@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa Saad Siddiqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease Movement Disorder Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenia Mamikonyan</last_name>
      <phone>215-615-3085</phone>
      <email>eugenia.mamikonyan@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Nabila Dahodwala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Shabo</last_name>
      <phone>215-503-3213</phone>
      <email>Leah.Shabo@Jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Tsao-Wei Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shonna Jenkins</last_name>
      <phone>843-732-9115</phone>
      <email>jenkisho@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Vanessa Hinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Univeristy</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farah Ismail</last_name>
      <phone>713-798-6902</phone>
      <email>farah.ismail@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Joohi Jimenez-Shahed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Neurological Institute/Movement Disorders Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia Arif</last_name>
      <phone>713-363-8390</phone>
      <email>carif@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>William Ondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 28, 2017</lastchanged_date>
  <firstreceived_date>October 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDD</keyword>
  <keyword>Parkinson's Disease Dementia</keyword>
  <keyword>patients taking a cholinesterase inhibitor.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Serotonin 5-HT2 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
